Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?

Literature DB >> 33214159

Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?

Sophia Zoungas¹, Kevan R Polkinghorne².

Abstract

Entities: Disease Gene

Keywords: diabetes mellitus; kidney disease; sodium-glucose transporter 2 inhibitors

Year: 2020 PMID： 33214159 PMCID： PMC7769032 DOI： 10.2215/CJN.16351020

Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN： 1555-9041 Impact factor: 8.237

× No keyword cloud information.

6 in total

1. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors: Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal: N Engl J Med Date: 2019-04-14 Impact factor: 91.245

2. Prediction of kidney-related outcomes in patients with type 2 diabetes.

Authors: Meg J Jardine; Jun Hata; Mark Woodward; Vlado Perkovic; Toshiharu Ninomiya; Hisatomi Arima; Sophia Zoungas; Alan Cass; Anushka Patel; Michel Marre; Giuseppe Mancia; Carl E Mogensen; Neil Poulter; John Chalmers
Journal: Am J Kidney Dis Date: 2012-06-12 Impact factor: 8.860

3. Dapagliflozin in Patients with Chronic Kidney Disease.

Authors: Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal: N Engl J Med Date: 2020-09-24 Impact factor: 91.245

4. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.

Authors: Ian H de Boer; M Luiza Caramori; Juliana C N Chan; Hiddo J L Heerspink; Clint Hurst; Kamlesh Khunti; Adrian Liew; Erin D Michos; Sankar D Navaneethan; Wasiu A Olowu; Tami Sadusky; Nikhil Tandon; Katherine R Tuttle; Christoph Wanner; Katy G Wilkens; Sophia Zoungas; Lyubov Lytvyn; Jonathan C Craig; David J Tunnicliffe; Martin Howell; Marcello Tonelli; Michael Cheung; Amy Earley; Peter Rossing
Journal: Kidney Int Date: 2020-07-10 Impact factor: 10.612

Review 5. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Authors: William G Herrington; David Preiss; Richard Haynes; Maximilian von Eynatten; Natalie Staplin; Sibylle J Hauske; Jyothis T George; Jennifer B Green; Martin J Landray; Colin Baigent; Christoph Wanner
Journal: Clin Kidney J Date: 2018-10-25

6. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m²: Subgroup Analysis of the Randomized CREDENCE Trial.

Authors: George Bakris; Megumi Oshima; Kenneth W Mahaffey; Rajiv Agarwal; Christopher P Cannon; George Capuano; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Hiddo J L Heerspink; Adeera Levin; Bruce Neal; Richard Oh; Carol Pollock; Norman Rosenthal; David C Wheeler; Hong Zhang; Bernard Zinman; Meg J Jardine; Vlado Perkovic
Journal: Clin J Am Soc Nephrol Date: 2020-11-19 Impact factor: 8.237